Skip to main content

Gerard Marti Aguasca

Institutions of which they are part

Cardiovascular Diseases
Vall Hebron Institut de Recerca

Gerard Marti Aguasca

Institutions of which they are part

Cardiovascular Diseases
Vall Hebron Institut de Recerca

Projects

Eficacia y seguridad de la doble antiagregación comparada con la combinación de anticoagulación oral+doble antiagregación en pacientes con fibrilación auricular de bajo-moderado riesgo sometidos a la implantación de un stent coronario

IP: Antonia Sambola Ayala
Collaborators: Gerard Marti Aguasca, Bruno García del Blanco, Pilar Tornos Mas
Funding agency: Ministerio Sanidad
Funding: 64900
Reference: EC11-473
Duration: 01/01/2012 - 31/12/2014

Características inmunohistoquímicas y moleculares del trombo resistente a la fibrinolisis

IP: Antonia Sambola Ayala
Collaborators: Gerard Marti Aguasca, Neus Bellera Gotarda, Imanol Otaegui Irurueta
Funding agency: Instituto de Salud Carlos III
Funding: 57475
Reference: PI09/01014
Duration: 01/01/2010 - 30/06/2014

Eficacia y seguridad de la doble antigregación comparada con aticoagulación oral+doble antiagregación en pacientes con fibrilación auricular de bajo-moderado riesgo sometidos a la implantación de un stent coronario

IP: Antonia Sambola Ayala
Collaborators: J. Bruno Montoro Ronsano, Bernat Serra Creus, Gerard Marti Aguasca, Imanol Otaegui Irurueta, Bruno García del Blanco, Pilar Tornos Mas
Funding agency: Ministerio Sanidad
Funding: 408000
Reference: TRA-200
Duration: 01/01/2010 - 31/12/2014

Estudio ACDC (Adherencia al Tratamiento en Pacientes Coronarios después de un Cateterismo con Colocación de un Stent Liberador de Fármacos). Seguimiento de dos años

IP: Ignacio Ferreira González
Collaborators: Aida Ribera Sole, Gerard Marti Aguasca, Bruno García del Blanco
Funding agency: Instituto de Salud Carlos III
Funding: 31884
Reference: PI09/90598
Duration: 01/01/2010 - 30/06/2011

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.

Related professionals

Ma Irene Valenzuela Palafoll

Ma Irene Valenzuela Palafoll

Predoctoral researcher
Genetics Medicine
Read more
Verónica Villagrasa Araya

Verónica Villagrasa Araya

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Monica Anglada Baguena

Monica Anglada Baguena

Coordinador/a
Quality, Processes and Document Management
Digital Transformation and Quality Area
Read more
Albert Vilanova Baldellou

Albert Vilanova Baldellou

Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.